# Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy

Source: https://onco.cc/trials/nct07743541/  
OnCo record `nct07743541` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TUB-040 run by Gilead Sciences, not yet recruiting.

## Summary

Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy is a phase 1/2 interventional study registered as NCT07743541 by Gilead Sciences, with 100 participants planned, started 2026-10. Conditions recorded: Uterine Endometrial Cancer. Interventions recorded: TUB-040 - Dose escalation and TUB-040 - RP2D.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07743541
- Phase: 1/2
- Setting: A Multicenter Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the NaPi2B Antibody-Drug Conjugate TUB-040 in Patients With Recurrent or Progressive Uterine Endometrial Cancer After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitor Therapy
- Sponsor: Gilead Sciences
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07743541: https://clinicaltrials.gov/study/NCT07743541

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [TUB-040](https://onco.cc/drugs/tub-040/)
- companies: [Tubulis (Gilead)](https://onco.cc/companies/tubulis/)

---
JSON: https://onco.cc/api/v1/entities/nct07743541.json